Cardio Catch-Up: Medtech Innovation Takes Center Stage At TCT 2022
Executive Summary
This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.
You may also be interested in...
Cardio Catch-Up: Boston Scientific's Next-Gen Watchman FLX Pro Reduces Thrombi Risk In Trials
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. Boston Scientific is promoting pre-clinical research of the next generation version of its Watchman left-atrial appendage closure device
Cardio Catch-Up: Medtronic, Abbott, Ancora Devices Headline ACC, CRT, THT
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition focuses on clinical trial presentations from three recent conferences: American College of Cardiology in New Orleans, Cardiovascular Research Technologies in Washington, DC, and Technology and Heart Failure Therapeutics in Boston.
Getting Personal With Boston Scientific's Global CMO Ken Stein: Taking The Long View To Innovate, Serve Patients
In this new series titled Getting Personal, we talk to new and veteran senior executives about their journeys to corporate leadership, their motivations, passions, and the peaks and valleys of running a medtech company. Medtech Insight talked with Ken Stein, Boston Scientific’s global chief medical officer about his own diagnosis with atrial fibrillation and advice for others living with the disease, innovative technologies in development at Boston Scientific, and some of his proudest and more challenging times on the job, as well as his advice for other physicians who are contemplating a move into the corporate world.